Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Scleroderma Clinical Trials
Scleroderma clinical trials are recruiting across 58 cities. Here are the cities with the most active studies:
Scleroderma Trial Phases
20 research organizations are sponsoring scleroderma trials.
About Scleroderma
Scleroderma is an autoimmune connective tissue disease characterized by hardening and tightening of the skin and connective tissues. Systemic sclerosis can also affect internal organs including lungs, kidneys, and heart. Treatment is directed at specific symptoms and organ involvement.
Clinical trials are advancing new treatments for scleroderma. Currently, 23 studies are recruiting a combined 4,366 participants across the United States. Research is being conducted by 20 organizations including AstraZeneca, University of Texas Southwestern Medical Center, Boehringer Ingelheim and 17 others.
2026 Scleroderma Research Landscape
As of October 2026, the scleroderma clinical trial landscape includes 23 actively recruiting studies across 58 cities in the United States. These studies are collectively seeking 4,366 participants, with an average enrollment target of 190 per study.
The research spans multiple phases of development: 13 studies are in PHASE2, 4 studies are in PHASE3, 4 studies are in NA, 2 studies are in PHASE1. The presence of Phase 3 trials indicates that some scleroderma treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 20 different organizations, including AstraZeneca, University of Texas Southwestern Medical Center, Boehringer Ingelheim, Scleroderma Research Foundation, Inc., Hospital for Special Surgery, New York, and 15 others. The large number of sponsors reflects significant research interest and investment in scleroderma treatment advancement.
Geographically, scleroderma trials are most concentrated in Chicago, Illinois (9 trials); Ann Arbor, Michigan (9 trials); Los Angeles, California (8 trials); New York, New York (6 trials); Phoenix, Arizona (5 trials) and 7 other cities.
Featured Scleroderma Studies
Highlighted recruiting studies for scleroderma, selected by enrollment size and research scope.
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability. Study details include: * Participants can transition in ROSY-S once they complete their participation in the parent study and ...
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country. The purpose of the registry is to learn more about morphea, specifically: * How morphea behaves over time * How frequently specific problems occur along with morphea (for example, arthritis) * Whether morphea has an autoimmune backgr...
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study...
Frequently Asked Questions About Scleroderma Clinical Trials
Are there scleroderma clinical trials near me?
Yes, there are 23 scleroderma clinical trials currently recruiting across 58+ cities in the United States, including Chicago, Illinois; Ann Arbor, Michigan; Los Angeles, California. Browse the studies above to find one at a location convenient for you.
How do I join a scleroderma clinical trial?
To join a scleroderma clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are scleroderma clinical trials free?
Yes, participation in scleroderma clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of scleroderma treatments are being studied?
Current scleroderma clinical trials are testing a range of approaches across PHASE2 (13 studies), PHASE3 (4 studies), NA (4 studies), PHASE1 (2 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 20 research organizations.
Is it safe to participate in scleroderma clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated October 13, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated October 13, 2026 · Data from ClinicalTrials.gov